Etentamig

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

What's the purpose of the trial?

The purpose of this study is to assess the safety and toxicity of ABBV-383 when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), daratumumab-dexamethasone (Dd), or nirogacestat (Niro) in adult patients with relapsed/refractory (R/R) multiple myeloma (MM).

Trial status

Accepting patients

Phase
Phase 1
Enrollment
320
Last Updated
5 months ago

Participating Centers

There are 21 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Daratumumab is a type of cancer drug called a monoclonal antibody. Daratumumab attaches to a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.
  • Dexamethasone is a corticosteroid that prevents the release of substances in the body that cause inflammation, and is given in conjunction with some cancer treatments.
  • Etentamig is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.
  • Lenalidomide is an oral immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow.
  • Pomalidomide is a kind of medication called an immunomodulatory agent that promotes an immune response to help slow tumor growth. Pomalidomide is used in the treatment of several different indications.

Published Results

Explore published results and other resources associated with this clinical trial (including press releases, news articles and videos).

ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study

As of May 15, 2024, 74 pts were enrolled and treated across 3 dose levels of ABBV-383 plus Dd. Median age was 69 years (range 39–89) and 45 (61%) pts were male. The majority of pts were White (n=65, 88%), 6 (8%) were Asian, and 3 (4%) were Black or African American. R-ISS at study entry was I in 18 (25%) pts, II in 26 (36%), and III in 15 (21%). Pts had received a median of 4 (range 3–9) prior lines of therapy; 70% were exposed to prior anti-CD38 mAb therapy. Forty-two (57%) pts were refractory to prior anti-CD38 mAb therapy, 34 (46%) were refractory to the most recent MM therapy, and 32 (43%) were triple-class refractory. After a median follow-up of 5 months (range 0–14), 48 (65%) pts remained on therapy; the majority of study drug discontinuations were due to progressive disease (n=14, 19%). Cytokine release syndrome (CRS) occurred in 20 (27%) pts. The majority of CRS events were grade 1 (n=8, 11%) or 2 (n=9, 12%); 3 (4%) pts had grade 3 events. Other most common treatment-emergent adverse events (AEs) included (any grade/grade 3–4) neutropenia (39%/38%), anemia (24%/18%), fatigue (22%/0%), and thrombocytopenia (30%/18%). Immune effector cell-associated neurotoxicity syndrome was reported in 2 (3%) pts total. Most common serious AEs were CRS (20%), COVID-19 pneumonia (7%), and pneumonia (5%). Twelve deaths occurred during the study to date; the most common cause was disease progression (n=5, 7%). At the time of data cutoff, 60 pts were evaluable for disease assessment. The aggregate overall response rate (ORR) for the total evaluable population was 70% (42/60). ORRs were 50% (7/14) in the 20-mg Q4W ABBV-383 cohort at a median follow-up of 1 month (range 0–14), 74% (26/35) in the 40-mg cohort at a median follow-up of 4.4 months (1–10), and 82% (9/11) in the 60-mg cohort at a median follow-up of 5.6 months (1–6). Median progression-free survival was not reached at time of analysis.

Conclusion: Preliminary data suggest ABBV-383 in combination with Dd is tolerable. Overall rates of CRS were low and early response rates were promising in the investigated population of heavily pretreated pts with MM.

7 months ago Read more

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.